Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedOct 16, 2025
DataAggregated Company Financials
Companies63
  • 7D-0.8%
  • 3M16.2%
  • 1Y-13.5%
  • YTD-3.9%

In the last week, Life Sciences has been flat. As for the longer term, the industry has declined 14% in the last year. Looking forward, earnings are forecast to grow by 14% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Oct 2025US$615.0bUS$144.3bUS$14.6b32.5x42.3x4.3x
Sat, 13 Sep 2025US$580.3bUS$144.3bUS$14.6b28.6x39.9x4x
Mon, 11 Aug 2025US$550.7bUS$144.2bUS$14.4b28.5x38.2x3.8x
Wed, 09 Jul 2025US$537.0bUS$142.9bUS$9.1b36x58.8x3.8x
Fri, 06 Jun 2025US$514.9bUS$142.9bUS$9.2b34.8x56.2x3.6x
Sun, 04 May 2025US$523.7bUS$142.4bUS$9.7b37.8x54.3x3.7x
Tue, 01 Apr 2025US$575.3bUS$142.5bUS$10.0b37.6x57.8x4x
Thu, 27 Feb 2025US$619.3bUS$143.3bUS$9.8b38.4x63.4x4.3x
Sat, 25 Jan 2025US$702.6bUS$142.4bUS$10.2b45.1x68.8x4.9x
Mon, 23 Dec 2024US$652.4bUS$142.4bUS$10.2b44.3x63.8x4.6x
Wed, 20 Nov 2024US$630.4bUS$142.4bUS$10.4b41.6x60.8x4.4x
Fri, 18 Oct 2024US$725.2bUS$141.8bUS$8.5b37.1x85.4x5.1x
Sun, 15 Sep 2024US$740.7bUS$141.8bUS$8.5b37.5x87.2x5.2x
Tue, 13 Aug 2024US$727.5bUS$141.5bUS$8.5b38.5x85.8x5.1x
Thu, 11 Jul 2024US$662.3bUS$141.3bUS$12.2b39.8x54.4x4.7x
Sat, 08 Jun 2024US$718.4bUS$141.3bUS$12.2b37.7x59x5.1x
Mon, 06 May 2024US$711.4bUS$141.7bUS$12.5b38.9x56.9x5x
Wed, 03 Apr 2024US$737.7bUS$142.0bUS$12.8b43.4x57.7x5.2x
Fri, 01 Mar 2024US$739.0bUS$142.2bUS$12.7b43.8x58x5.2x
Sun, 28 Jan 2024US$698.4bUS$153.8bUS$14.2b35.5x49.3x4.5x
Tue, 26 Dec 2023US$698.8bUS$153.8bUS$14.2b37.5x49.1x4.5x
Thu, 23 Nov 2023US$616.3bUS$153.8bUS$14.0b33.5x44x4x
Sat, 21 Oct 2023US$607.7bUS$154.6bUS$11.2b31.3x54.2x3.9x
Mon, 18 Sep 2023US$697.4bUS$154.6bUS$11.2b33.4x62.2x4.5x
Wed, 16 Aug 2023US$719.3bUS$154.7bUS$11.4b32.4x62.9x4.7x
Fri, 14 Jul 2023US$704.1bUS$155.5bUS$12.7b29.1x55.5x4.5x
Sun, 11 Jun 2023US$680.2bUS$152.4bUS$12.5b29.1x54.4x4.5x
Tue, 09 May 2023US$697.5bUS$152.4bUS$12.9b30.5x54.2x4.6x
Thu, 06 Apr 2023US$722.3bUS$154.6bUS$10.8b26.7x66.9x4.7x
Sat, 04 Mar 2023US$739.7bUS$154.5bUS$10.9b31x68x4.8x
Mon, 30 Jan 2023US$761.7bUS$155.5bUS$9.0b31.1x84.7x4.9x
Wed, 28 Dec 2022US$744.3bUS$155.2bUS$8.8b28.6x84.8x4.8x
Fri, 25 Nov 2022US$762.8bUS$155.1bUS$8.8b28.3x87x4.9x
Sun, 23 Oct 2022US$691.5bUS$152.9bUS$17.4b24.8x39.6x4.5x
Price to Earnings Ratio

39.6x


Total Market Cap: US$691.5bTotal Earnings: US$17.4bTotal Revenue: US$152.9bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 61.8x202320242025
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 42.3x which is lower than its 3-year average PE of 61.8x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 5.9% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.18%
Healthcare-1.14%
Life Sciences-0.81%
Clinical Research and Equipment-0.81%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DHR DanaherUS$206.100.6%
+US$816.3m		-23.1%PE43.2x
IQV IQVIA HoldingsUS$203.121.3%
+US$428.4m		-12.8%PE27.9x
WAT WatersUS$332.411.5%
+US$283.3m		-6.1%PE29.9x
BRKR BrukerUS$36.204.5%
+US$238.2m		-40.9%PE69x
ADPT Adaptive BiotechnologiesUS$17.1110.0%
+US$237.5m		256.5%PS12.7x

Latest News

ADPT
US$17.11
Adaptive Biotechnologies
7D
10.0%
1Y
256.5%

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors

Oct 16
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) 31% Jump Shows Its Popularity With Investors
TMO
US$527.87
Thermo Fisher Scientific
7D
-1.6%
1Y
-10.8%
ILMN
US$93.00
Illumina
7D
-4.9%
1Y
-35.4%
AVTR
US$13.87
Avantor
7D
0.9%
1Y
-44.1%
QSI
US$2.63
Quantum-Si
7D
48.6%
1Y
222.1%
TEM
US$91.91
Tempus AI
7D
-11.0%
1Y
87.4%

Expanding Genomic Testing And AI Will Build Lasting Healthcare Value

Tempus AI's fair value estimate has been raised by analysts from $74.82 to $77.55 per share. This reflects optimism about improved revenue growth and updated market outlooks.
MEDP
US$514.32
Medpace Holdings
7D
-3.1%
1Y
48.4%

Tech-enabled Clinical Trials Will Balance Potential Risk And Reward

Analysts have raised Medpace Holdings’ fair value estimate modestly, from $423.64 to $428.00. Industry views reflect improved biotech funding and solid bookings, although some ongoing uncertainty in demand signals remains.
WAT
US$332.41
Waters
7D
1.5%
1Y
-6.1%

Pharmaceutical R&D And Merger Will Unlock Future Market Potential

Analysts have raised their price target for Waters to $351.07 from $347.14, citing expectations of stronger profit margins and steady revenue growth ahead. What's in the News Waters Corporation raised its earnings guidance for the full year 2025 and projects constant currency sales growth between 5.5% and 7.5%.
WST
US$262.95
West Pharmaceutical Services
7D
-1.9%
1Y
-9.0%
IQV
US$203.12
IQVIA Holdings
7D
1.3%
1Y
-12.8%

NVIDIA Partnership And AI Analytics Will Reshape Life Sciences

Analysts have slightly increased their price target for IQVIA Holdings from approximately $215.89 to $218.26. They cite improved demand momentum, strong segment performance, and business resilience relative to peers as reasons for the adjustment.
MTD
US$1,304.00
Mettler-Toledo International
7D
-1.8%
1Y
-7.2%
A
US$139.65
Agilent Technologies
7D
-0.8%
1Y
0.4%

Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress

Agilent Technologies received a modest analyst price target increase from $138.83 to $140.97. This reflects analysts' expectations for stable growth and slightly improved long-term valuation metrics.
BRKR
US$36.20
Bruker
7D
4.5%
1Y
-40.9%
DHR
US$206.10
Danaher
7D
0.6%
1Y
-23.1%
ICLR
US$187.85
ICON
7D
0.7%
1Y
-36.0%
STVN
US$23.93
Stevanato Group
7D
-2.6%
1Y
30.4%

Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings

Sep 22
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings